DOXORUBICIN

Carcinoma Of Urethra

University of Southern CaliforniaSmall moleculePhase 3Active

BB

70/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 95/ 100

Competitive context

7 Active assets in the Carcinoma Of Urethra cohort.

Asset / Sponsor	Phase	Rating
CIS-DIAMMINEDICHLOROPLATINUM II University of Southern California	Phase 3	BBB
Carboplatin National Cancer Institute (NCI)	Phase 3	BBB
VINBLASTINE University of Southern California	Phase 3	BBB
METHOTREXATE University of Southern California	Phase 3	BBB
Docetaxel Eli Lilly and Company	Phase 2	B

View all 37 →

Same molecule, other indications

DOXORUBICIN is also rated in:

adult acute lymphoblastic leukemiaActive

BBB

Indicative · Phase 4

77 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative · Phase 3

76 / 100

hematopoietic and lymphoid system neoplasmActive

BBB

Indicative · Phase 4

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.